We specialize in Next-Generation Sequencing (NGS)-based molecular diagnostics, focusing on identifying genetic mutations and abnormalities with advanced AI integration. Our services enable early detection and personalized treatment plans, particularly in oncology.

Our personalized healthcare utilizes NGS and AI technologies to tailor medical treatments based on individual genetic profiles. This approach enhances therapy effectiveness, minimizes adverse effects, and ensures tailored care aligned with each patient's genetic makeup.

We offer genetic disease predisposition analysis using NGS to predict susceptibility to hereditary conditions along with pharmacogenomics for recommendation of patient-centred drugs. This service supports proactive healthcare measures and informed decision-making for patients and healthcare providers.

We envision to integrate AI into NGS to conduct population-wide genetic screening aimed at improving public health outcomes. Our initiatives will help identify prevalent health risks and design targeted community health programs for disease prevention and management.

We leverage over a decade of experience in NGS and AI to pioneer advancements in cancer research. Our focus includes uncovering novel biomarkers and genetic insights, collaborating with leading institutions to develop more effective diagnostic tools and therapeutic strategies.